We’re excited to share a major milestone from CAGE Bio Inc., a Propel(x) portfolio company, which has reported positive Phase 2b clinical trial results for its lead program, CGB-500, in atopic dermatitis.
The Phase 2b multi-center, double-blind clinical trial demonstrated strong efficacy and safety outcomes. These results represent a significant achievement for the CAGE Bio team, which has successfully advanced breakthrough science from the laboratory to meaningful clinical data in just a few years.
Beyond this milestone, CAGE Bio Inc. is expanding its clinical and strategic footprint through several key initiatives:
- New collaboration with Mayo Clinic, supported by an investment from Mayo Clinic Ventures, to advance therapies for cutaneous graft-versus-host disease (GVHD)
- Two strategic R&D partnerships with leading pharmaceutical companies, with potential to scale into broader collaborations
CAGE Bio Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and immune-related diseases, addressing areas of significant unmet medical need.
At Propel(x), we’re proud to have supported CAGE Bio Inc. twice through our platform and look forward to their continued progress in bringing impactful therapies to patients worldwide.
Many congratulations to CEO Nitin Joshi, Samir Mitragotri; Justin M Ko; Marina Shevachman; Drew Sturtevant, Ph.D.; Jason Mars; Shashwati Godbole, MS, PMP; Patricia Oto, RPh; Kirsten Reiman; Srinivas Sripada; Carmine Durham; Jeff Keyser, Ph.D., RPh, JD.
Register on Propelx to invest in the future of innovation
https://www.propelx.com/
